幽门螺杆菌根除方案DUE评价模式的建立与应用

目的：建立本院幽门螺杆菌根除方案的药物利用评价（Drug use evaluation，DUE）标准，为合理治疗幽门螺杆菌提供依据。方法：根据建立的幽门螺杆菌（Hp）根除治疗方案的DUE标准，采用回顾性方法，对本院2019年1月～12月行Hp检测的患者，从用药指征、用药过程、用药结果进行评价与分析。结果：用药指征合理率为99.8%；用药过程中有73.9%的药物方案选择合理，用法用量合理率为78.0%，治疗疗程合理率为98.3%；用药结果合理率为12.8%。结论：依照所建立的Hp根除方案的药物利用评价标准，并对本院Hp根除治疗方案进行评估，可发现治疗过程中的缺陷，为规范幽门螺旋杆菌的药物治疗提供参考。

Establishment and Application of DUE Mode in the Helicobacter Pylori Eradication Therapy

Objective: To establish drug utilization evaluation (DUE) criteria of the eradication therapy for Helicobacter pylori (Hp) and provide basis for rational treatment in our hospital. Methods: According to the established DUE criteria of the eradication therapy for Hp, a retrospective method was adopted to evaluate and analyze the indications, courses and results of the medication for patients undergoing Hp tests in our hospital from January 2019 to December 2019. Results: The rational rate of indications for drug use was 99.8%. In the course of medication, 73.9% of the drug regimens were reasonably selected, the rational rate of drug usage and dosage was 78%, the rational rate of course of treatment was 98.3%. The rational rate of drug use result was 12.8%. Conclusion: According to the established evaluation criteria, defects in the treatment process can be found by evaluating the HP eradication treatment program in our hospital, which can provide reference for standardizing the treatment of Helicobacter pylori.